Mandate Vinge advises Oncopeptides in connection with a directed share issue

January 25, 2019

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 546 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Jefferies International Limited, Carnegie Investment Bank AB (publ) and DNB Markets, a part of DNB Bank ASA.

Oncopeptides is a clinical development pharmaceutical company focused on conducting anti cancer research to develop treatments for the benefit of patients. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Johan Winnerblad, Rikard Lindahl and Hampus Olsson.

Vinge is awarded “The Top Firm in Sweden” in WTR 1000’s latest ranking

Vinge receives the highest ranking in the World Trademark Review list of the year’s rankings. The firm obtains the Guide’s foremost ranking, which also highlights specific experts.
February 18, 2021

Insurance services in Sweden – a summary 2021

Vinge’s insurance team has written a brief summary of some of the main features of the Swedish regulations affecting foreign insurers with existing or contemplated business activities in Sweden.
February 09, 2021

Summary of employment related news in Sweden as of January 2021

Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021